SCLX:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.976

Change

-0.09 (-8.79)%

Market Cap

N/A

Volume

5.16M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-07 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

+0.84 (+1.32%)

USD 203.14B
AMGN Amgen Inc

+0.12 (+0.04%)

USD 172.97B
SNY Sanofi ADR

+0.47 (+0.92%)

USD 134.67B
GILD Gilead Sciences Inc

+6.21 (+6.77%)

USD 111.44B
BIIB Biogen Inc

-0.48 (-0.28%)

USD 25.32B
GRFS Grifols SA ADR

+0.45 (+4.97%)

USD 6.92B
AMRN Amarin Corporation PLC

-0.02 (-2.84%)

USD 0.26B
MIRA MIRA Pharmaceuticals, Inc. Com..

-0.01 (-0.59%)

USD 0.03B
SCLXW Scilex Holding Company

-0.12 (-25.70%)

N/A

ETFs Containing SCLX

BTEC 0.00 % 0.42 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -52.16% 20% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -52.16% 20% F 14% F
Trailing 12 Months  
Capital Gain -24.34% 30% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.34% 30% F 23% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -34.63% 10% F 5% F
Dividend Return -34.63% 10% F 5% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 36.87% 30% F 52% F
Risk Adjusted Return -93.92% 10% F 5% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector